Pancreatic adenocarcinoma accounts for nearly 90–95% of exocrine malignant tumors of
the pancreas. Traditionally, overexpressed proteins/epitopes such as CA 19-9, CA-50, CEA …

Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The
lack of early symptoms results in latestage detection and a high mortality rate. Currently, the …

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States.
There has been minimal progress with regard to cancer-specific outcomes in recent …

Pancreatic ductal adenocarcinoma is one of the most difficult malignancies to diagnose and
treat. The aim of this article is to review how tumor markers can aid the diagnosis and …

The low prevalence of pancreatic cancer remains an obstacle to the development of
effective screening tools in an asymptomatic population. However, development of effective …

Biomarkers play an essential role in the management of patients with invasive cancers.
Pancreatic ductal adenocarcinoma (PDC) associated with poor prognosis due to advanced …

Background The prognosis of pancreatic cancer remains poor, mainly because of its
aggressive biological behaviour and late clinical diagnosis, which precludes the application …

CA 19-9 and CEA are the most commonly used biomarkers for diagnosis and management
of patients with pancreatic cancer. Since the original compendium by Steinberg in 1990 …

Background Serum carbohydrate antigen (CA 19-9) is the most common tumor marker
assessed in pancreatic cancer patients; nevertheless few articles have comprehensively …

Serum CA 19‐9 is the only FDA approved biomarker recommended for use in the routine
management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies …